Doximity's stock skyrockets 50% on medical AI excitement. Can the rally last?
Doximity (DOCS) shares rose as much as 94% and were up about 50% after its earnings call, despite mixed results. Management highlighted medical AI progress, including a “winning model” with 4.8% error vs 13.6% for Anthropic’s Fable 5, and said it earns over 10x search revenue vs cost. FY revenue guidance was raised to $671M-$681M from $664M-$676M; adjusted EPS was 29 cents.
How this was made
The 30-second read
Why it matters
The article ties the stock’s outsized move to (1) raised FY revenue guidance and (2) management’s AI progress claims, while also presenting a counterargument that AI is not yet monetizing meaningfully and could erode core revenue streams.
Market read
Traders get a same-day catalyst mix: a guidance raise with specific AI performance and monetization claims, plus explicit sell-side skepticism about AI’s near-term revenue impact.
What to watch
The article notes mixed adjusted EPS (29 cents, penny short) and a core-business cannibalization risk tied to Doximity’s physician-targeted ad model.
Background
Doximity operates a medical networking platform and is increasingly emphasizing medical AI, including a clinical AI search product and physician-editor review workflow.
Ticker impact
Doximity shares surged after management raised FY revenue guidance to $671M-$681M and highlighted AI search economics on the earnings call.
Near-term momentum likely remains elevated, but upside may fade if investors conclude AI revenue is not yet material versus core ad and recruiting revenue.
The text provides concrete guidance uplift and specific AI performance/economics claims, while also citing a sell-side concern that AI contributes negligibly and could cannibalize the core business.
Market effects
Highlights investor appetite for applied healthcare AI and clinical-evidence tooling, potentially lifting sentiment for adjacent health-tech software names.
Primarily US small/mid-cap growth sentiment, with limited direct regional spillover implied.
Limited global read-through beyond healthcare AI enthusiasm and model-performance benchmarking.
Counterpoint
AI may be a headline driver, but if management’s guidance does not assume material AI contribution, the rally could reverse as investors reprice fundamentals.
Key entities
- companyDoximity
Medical networking platform whose shares jumped on AI excitement, raised FY revenue guidance, and earnings-call AI commentary.
- personJeff Tangney
CEO who cited a 4.8% error rate for Doximity’s winning model and discussed AI search unit economics.
- personNate Gross
Co-founder who departed for OpenAI healthcare strategy, referenced as a talent loss risk.
- organizationStanford and Harvard researchers
Published an independent preprint benchmarking 24 clinical AI models, referenced for Doximity’s model performance.
